Agree EH Assumption of peak adoption of 3% seems super conservative.
For what its worth, in the March 2023 investor update webinar, they had independent research company, Triangle Insights present the results of their market research of dermatologists, re prospective prescription preferences. 42% nominated SB as their 1st line of treatment. 50% nominated SB as their 2nd line choice. Safety, efficacy and ease of application were the big positives. Price compared to other treatments is why the preferences weren't even higher.
You can argue about the independence and validity of the figures, but in my opinion, clearly Vinnie is not negotiating with BP on the basis of potential 3% market share for a best in class product...
Agree EH Assumption of peak adoption of 3% seems super...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $527.6M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 32083 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 50000 | 3 |
View Market Depth
| Last trade - 16.16pm 20/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
Day chart unavailable